Table 2. Differences in outcome in patients with CNS relapse, allocated either transplantation or chemoradiotherapy according to whether they received Idarubicin or Mitoxantrone.
| c-CNS | i-CNS | |||
| n | 43 | 80 | ||
| Ida | Mito | Ida | Mito | |
| Induction | ||||
| n | 15 | 28 | 29 | 51 |
| TRM | 2 | 1 | 1 | 3 |
| Failure | 1 | 2 | 0 | 1 |
| Withdrawn | 0 | 1 | 0 | 1 |
| Allocated Treatment* | ||||
| n | 12 | 24 | 28 | 46 |
| SCT | 9 | 21 | 25 | 36 |
| No SCT | 3 | 3 | 3 | 10 |
| Post Induction | ||||
| n | 12 | 24 | 28 | 46 |
| TRM | 0 | 0 | 2 | 2 |
| Relapse | 1 | 3 | 2 | 1 |
| Withdrawn | 0 | 2 | 0 | 2 |
| SCT Time point | ||||
| Not Reached | 0 | 0 | 0 | 3 |
| Reached | 11 | 19 | 24 | 38 |
| Outcome | ||||
| SCT Group | 8 | 16 | 21 | 30 |
| Actual SCT | 8 | 15 | 13 | 21 |
| CR2 | 3 | 12 | 5 | 16 |
| TRM | 3 | 1 | 1 | 2 |
| Relapse | 2 | 2 | 6 | 3 |
| Accidental Death | 0 | 0 | 1 | 0 |
| No-SCT | 0 | 1 | 8 | 9 |
| CR2 | 0 | 0 | 0 | 4 |
| TRM | 0 | 1 | 0 | 0 |
| Relapse | 0 | 0 | 8 | 5 |
| Non-SCT Group | 3 | 3 | 3 | 8 |
| Actual non-SCT | 3 | 2 | 3 | 6 |
| CR2 | 1 | 1 | 3 | 5 |
| TRM | 1 | 0 | 0 | 0 |
| Relapse | 1 | 1 | 0 | 1 |
| SCT | 0 | 1 | 0 | 2 |
| CR2 | 0 | 1 | 0 | 1 |
| Second Malignancy | 0 | 0 | 0 | 1 |
c-CNS = combined CNS relapse; i-CNS = isolated CNS relapse; TRM = Therapy related mortality; SCT = allogeneic transplantation; CR2 = second remission; Ida = Idarubicin; Mito = Mitoxantrone. *Patients allocated SCT were, all those with very early relapse; early i-CNS relapses and early and late c-CNS relapses with MRD ≥10−4 at the end of induction. Where MRD was not evaluable, decision to transplant was based on duration of CR1. All other patients were allocated chemoradiotherapy.